These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11022712)

  • 41. Efficacy over time of LHRH analogs in the treatment of PCa--a prospective analysis using serum testosterone to determine dosing intervals.
    Greil S; Robinson EA; Singal B; Kleer E
    Urology; 2009 Mar; 73(3):631-4. PubMed ID: 19110301
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preliminary clinical evaluation of leuprorelin acetate depot injection in France, in the management of prostatic cancer.
    Navratil H
    J Int Med Res; 1990; 18 Suppl 1():69-73. PubMed ID: 2108887
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Recent advance in luteinizing hormone-releasing hormone analogue therapy in management of prostate cancer].
    Kawai K; Akaza H
    Nihon Rinsho; 1998 Aug; 56(8):2108-13. PubMed ID: 9750517
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Luteinizing hormone-releasing hormone for prostate cancer in a hemodialysis patient: a case report].
    Mizusawa H; Kontani K; Okaneya T; Yoneyama T
    Hinyokika Kiyo; 1997 Jun; 43(6):421-3. PubMed ID: 9250492
    [TBL] [Abstract][Full Text] [Related]  

  • 45. What should I know about Lupron Depot for treating prostate cancer?
    Johns Hopkins Med Lett Health After 50; 2012 Jan; 23(11):7. PubMed ID: 22396997
    [No Abstract]   [Full Text] [Related]  

  • 46. Leuprolide acetate-induced dermatitis herpetiformis.
    Grimwood RE; Guevara A
    Cutis; 2005 Jan; 75(1):49-52. PubMed ID: 15732435
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the effects of leuprorelin acetate and danazol treatments on serum CA-125 levels in women with endometriosis.
    Matalliotakis IM; Arici A; Goumenou AG; Katassos T; Karkavitsas N; Koumantakis EE
    Int J Fertil Womens Med; 2004; 49(2):75-8. PubMed ID: 15188832
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative in vitro release and clinical pharmacokinetics of leuprolide from Luphere 3M Depot, a 3-month release formulation of leuprolide acetate.
    Park S; Kim DH; Kim Y; Park JH; Lee M; Song IS; Shim CK
    Drug Dev Ind Pharm; 2017 Mar; 43(3):441-447. PubMed ID: 27824264
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Adverse reaction of LH-RH agonist and its countermeasure].
    Oishi K
    Nihon Rinsho; 2000 Jul; 58 Suppl():202-5. PubMed ID: 11022714
    [No Abstract]   [Full Text] [Related]  

  • 50. [Total androgen blockade].
    Namiki M; Mizokami A
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():193-8. PubMed ID: 12599570
    [No Abstract]   [Full Text] [Related]  

  • 51. Leuprolide acetate-induced generalized papular eruption.
    Burris K; Ding CY; Lim GF
    J Drugs Dermatol; 2014 Jun; 13(6):755-7. PubMed ID: 24918569
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration.
    Meinhardt W; Horenblas S
    J Urol; 1999 Jul; 162(1):170-1. PubMed ID: 10379778
    [No Abstract]   [Full Text] [Related]  

  • 53. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
    Ohuchi H; Noguchi K; Kinoshita Y; Hosaka M; Kawasaki C; Miura T; Kondo I; Harada M
    Hinyokika Kiyo; 2000 Aug; 46(8):531-6. PubMed ID: 11019371
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Combination effect of flutamide and leuprorelin acetate on growth of Dunning R3327-H prostatic adenocarcinoma in rats].
    Tomura A; Kuroiwa S; Okada M; Abe F
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):563-9. PubMed ID: 9530363
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration.
    Dearnaley DP; Norman AR; Shahidi M
    J Urol; 1999 Jul; 162(1):170. PubMed ID: 10379777
    [No Abstract]   [Full Text] [Related]  

  • 56. [Treatment of uterine leiomyoma with depot leuprorelin acetate (Enantone-Gyn monthly depot). Effect on leiomyoma volume and operability. German Leuprorelin Study Group].
    Stolz W; Pfützenreuter N
    Zentralbl Gynakol; 1997; 119(10):468-75. PubMed ID: 9432825
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Characteristics, effects, side effects of the LH-RH agonist].
    Miyanaga N; Akaza H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():177-81. PubMed ID: 12599567
    [No Abstract]   [Full Text] [Related]  

  • 58. Eligard. Tiny implant fights prostate cancer.
    Nursing; 2002 May; 32(5):18. PubMed ID: 12035639
    [No Abstract]   [Full Text] [Related]  

  • 59. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Bone loss induced by GnRH agonist treatment].
    Onoe Y; Ohta H
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():702-5. PubMed ID: 15035212
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.